Individuality Clinical Trial
— LabExMIOfficial title:
Genetic & Environmental Determinants Of Immune Phenotype Variance: Establishing A Path Towards Personalized Medicine
The purpose of this study is to assess the determinants of immunologic variance within the general healthy population.
Status | Completed |
Enrollment | 1012 |
Est. completion date | August 2013 |
Est. primary completion date | August 2013 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 20 Years to 69 Years |
Eligibility |
Inclusion Criteria: 1. Subjects considered as healthy by the investigator based on medical history, clinical examination, laboratory results and ECG (blood sampling for laboratory assessments and ECG should be done at V0 and only after signed informed consent). 2. Subjects who, according to the investigator, can and will comply with the requirements of the protocol and are available for all scheduled visits at the investigational site. 3. Healthy male or female aged between 20 and 69 (included) years 4. Metropolitan French origin for 3 generations 5)18.5 =BMI = 32 kg/m² (Appendix 18.6) 6)Ability to give their informed consent in writing 7)Must understand spoken and written French 8)Affiliated to the French social security or assimilated regimens 9)Registered on the French "Fichier des Volontaires se prêtant à la Recherche Biomédicale (VRB)" Exclusion Criteria: 1. Subjects who can not participate according to their status on the registry mentioned at Art L. 1121-16 of the French Public Health Code 2. Participation in another clinical study in the last 3 months in which the subject has been exposed to an investigational product (pharmaceutical product or placebo or medical device) or concurrent participation in another clinical study during the study period 3. Relatedness to previously recruited individuals in the study cohort 4. Travel in (sub-)tropical countries within the last 3 months 5. For women: pregnant or breastfeeding or intending to become pregnant or peri-menopausal* * Peri-menopausal women as defined by menstrual irregularity: either a change in the menstrual cycle length of more than seven days (early perimenopause) or two or more missed periods with an interval of 60 days or more between periods (late perimenopause) (Stages of Reproductive Aging Workshop, STRAW)(11) 6. Any physical exercise within the last 8 hours before inclusion (V1) and before (V2) 7. Subjects following a special diet for medical reasons as prescribed by a GP or dietician (e.g. calorie restricted or weight-loss diet for significant overweight, cholesterol lowering diet or subjects suffering from any clinically diagnosed food allergy or intolerance) 8. Alcohol abuse (more than 50 g of pure ethanol per day: for example, more than 4 x 150 mL glasses of wine, more than 4 x 250 mL glasses of beer, more than 4 x 40 mL glasses of high alcohol content drinks) 9. Illicit drug use or substance abuse within 3 months prior to inclusion 10. Presence of evidence of neurological or psychiatric diagnoses which, although stable, are deemed by the investigator to render the potential subject unable/unlikely to participate in the study satisfactorily. 11. Severe/chronic/recurrent pathological conditions, 12. Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within the 6 months prior to the inclusion. For corticosteroids, this will mean a dose equivalent to 20 mg/day of prednisone or equivalent for > 2 weeks (inhaled and topical steroids allowed) 13. Chronic administration of NSAIDs, including aspirin: prolonged intake (> 2 weeks) within 6 months before study or any intake within the 7 days preceding skin biopsy [exception for low dose aspirin: maximum 250mg/daily, see 8.1] 14. Receipt of any vaccination 3 months before the inclusion or planning to receive any vaccination during the study 15. Receipt of blood products or immunoglobulins within 3 months prior the inclusion or planning to receive blood products or immunoglobulins during the study 16. Hemoglobin measurement less than 10.0 g/dL for women and less than 11.5 g/dL for men 17. Platelet count less than 120.000/mm3 18. ALAT and/or ASAT > 3 times the upper limit of the norm (ULN) 19. Allergy to lidocaine |
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research
Country | Name | City | State |
---|---|---|---|
France | BIOTRIAL | Rennes |
Lead Sponsor | Collaborator |
---|---|
Institut Pasteur |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Measurement of cytokine/chemokine stimulated by 40 pattern-recognition receptors agonists (PRR agonists) or immune stimulators. | V2 (28days after V1) | No | |
Secondary | Determination of genotype-to-phenotype associations at a mechanistic level | 4 days after V0 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02478021 -
Effects of Hydrocortisone on Social Cognition and Memory
|
N/A | |
Completed |
NCT02906306 -
Effects of Individual and Group Occupational Therapy on General Self-Efficacy, Psychological Well-Being, Personal Independence and Occupational Therapy in Older Adults
|
N/A | |
Completed |
NCT03905993 -
Milieu Intérieur Collection - Genetic & Environmental Determinants Of Immune Phenotype Variance
|
||
Terminated |
NCT02296359 -
Vaccination Response in Individual Monozygotic Twins
|
N/A | |
Terminated |
NCT02654704 -
Vaccination Responses in Young and Older Adults
|
||
Recruiting |
NCT02294448 -
PopPK Profile of Qishe Pill: Study Protocol for a Phase I Clinical Trial
|
Phase 1 | |
Recruiting |
NCT05201534 -
Interventions in Mathematics and Cognitive Skills
|
N/A | |
Completed |
NCT02478034 -
Effects of Mineralocorticoid Receptor Stimulation on Cognition
|
N/A | |
Completed |
NCT02071485 -
Non-Invasive Brain-Computer Interface for Virtual Object Control
|
N/A | |
Completed |
NCT02102191 -
Acute Physiological Effects of Electronic Sigarette vs Cigarette Smoking
|
N/A | |
Recruiting |
NCT03147443 -
Evaluating the Effects of Traditional Chinese Medicine by N-of-1 Trials
|
Phase 4 | |
Completed |
NCT01748071 -
The Realtime Detection for Individual Variation of Analgesic :A Comparison of Sufentanil vs Fentanyl
|
N/A | |
Completed |
NCT02070614 -
Association of CYP3A4 rs2242480 With Sufentanil Plasma Concentration and PCA Consumption
|
N/A | |
Recruiting |
NCT04601792 -
A Series of N-of-1 Trials of Traditional Chinese Medicine Based on Bayesian Method
|
Phase 4 | |
Completed |
NCT02761031 -
Perioperative Heart Rate Variability Analysis in Realtime
|
||
Completed |
NCT02768636 -
Can Omega-3 Improve Heart Rate Variability Measurement?
|
Phase 4 | |
Completed |
NCT01868152 -
The Realtime Detection for Prediction of Opioid Analgesic
|
N/A |